Viracta Therapeutics
Cardiff By The Sea
About Viracta Therapeutics
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $50K – $100K
- Total funding: $234.9M
- Funding stage: IPO
- Last round: Post-IPO Debt (Nov 2021)
- Ticker: nasdaq:VIRX
- Website: viracta.com
- Phone: (858)400-8470
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/viracta-therapeutics-76043 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.